American Association for Cancer Research

SHERPA: Unknown

People

  1. Jhaveri
    Jhaveri
  2. Modi
    Modi
  3. Chandarlapaty
    Chandarlapaty
  4. Hudis
    Hudis
  5. Razavi
    Razavi
  6. Ladewig
    Ladewig
  7. Norton
    Norton
  8. Solit
    Solit
  9. Chiosis
    Chiosis
  10. Drago
    Drago

Groups

  1. Breast Medicine Service (42)
  2. Department of Medicine (42)
  3. Solid Tumor Oncology Division (42)
  4. GSK Faculty (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  6. Human Oncology and Pathogenesis Program (9)
  7. Radiology, Department of (9)
  8. Sloan Kettering Institute Postdocs (9)
  9. Survivorship Research (9)
  10. Hematology-Oncology Fellows (8)
Search Within
  1. "Komal Jhaveri"
Formats
  1. Meeting Abstract (31)
  2. Journal Article (11)
Groups
  1. Breast Medicine Service (42)
  2. Department of Medicine (42)
  3. Solid Tumor Oncology Division (42)
  4. GSK Faculty (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  6. Human Oncology and Pathogenesis Program (9)

More Groups

People
  1. Komal Jhaveri (42)
  2. Shanu Modi (9)
  3. Sarat Chandarlapaty (7)
  4. Maurizio Scaltriti (6)
  5. Clifford Hudis (5)
  6. Pedram Razavi (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (13)
  4. 2020 (12)
  5. 2019 (6)
  6. 2018 (4)

More Years

Publications
  1. Cancer Research (33)
  2. Clinical Cancer Research (9)

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ia/b study of giredestrant ± palbociclib and ± luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; Bellet, M.; Turner, N. C.; Loi, S.; Bardia, A.; Boni, V.; Sohn, J.; Neilan, T. G.; Villanueva-Vázquez, R.; Kabos, P.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation
    Journal Article

    Ladewig, E.; Michelini, F.; Jhaveri, K.; Castel, P.; Carmona, J.; Fairchild, L.; Zuniga, A. G.; Arruabarrena-Aristorena, A.; Cocco, E.; Blawski, R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer
    Journal Article

    Jhaveri, K.; Juric, D.; Yap, Y. S.; Cresta, S.; Layman, R. M.; Duhoux, F. P.; Terret, C.; Takahashi, S.; Huober, J.; Kundamal, N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: Correlative study of AZD9496 oral SERD phase I trial
    Meeting Abstract

    Cani, A. K.; Dolce, E. M.; Darga, E. P.; Hu, K.; Brown, M.; Liu, C. J.; Pierce, J.; Bradbury, K.; Aung, K.; Schiavon, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kα inhibitors
    Journal Article

    Cai, Y.; Xu, G.; Wu, F.; Michelini, F.; Chan, C.; Qu, X.; Selenica, P.; Ladewig, E.; Castel, P.; Cheng, Y.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Meeting Abstract

    Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
    Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: